Entry level $16 = Target price $19.50 = Stop loss $15
Significant break above 200ma.
Average analysts price target $37 | Buy rating
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics...
Following my ideas redarding #cellectis. A promising french biotech company that already celebrates hugh success with "their" ucart19 against leukemia. Check out my thoughts and join the conversatioin.
- Double bottom which is normally an indicator for a reversal.
- higher high and higher low
- Oversold Stoch RSI (4hr)